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A Case of Galactorrhea Associated with Excitalopram 
 
 
 
Escitalopram is one of the most popular selective serotonin reuptake inhibitors (SSRIs) in 
current use as a first-line treatment for depression. Escitalopram is well-tolerated and rarely 
associated with serious side effects. Endocrine and reproductive side effects of serotonergic 
antidepressants are uncommon and galactorrhea is very rarely mentioned among SSRI-
related side effects. Serotonin-enhancing antidepressants may result in a rise in prolactin 
levels through suppression of dopamine neurotransmission. In the present study, we report 
a case of hyperprolactinemic galactorrhea associated with escitalopram. A 36-year-old woman 
developed galactorrhea after initiation of escitalopram for depression and was found to have 
an elevated prolactin level. Escitalopram was discontinued with resolution of the patient’s 
galactorrhea and normalization of her prolactin level. 
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Introduction 
 
All conventional antipsychotic drugs block D2 receptors on lactotroph cells and thus
remove the main inhibitory influence on prolactin secretion.
1,2 However, monoamine 
oxidase inhibitors, some tricyclic antidepressants, and rarely selective serotonin re-
uptake inhibitors (SSRIs) may increase plasma prolactin levels. With the increasing 
use of SSRIs, treating physicians are faced with uncommon side effects, some of which 
were incompletely documented at the time of the launch of these medications. Citalop-
ram is one of the newest SSRIs, and it has a higher affinity for antiserotoninergic 
receptors than the other SSRIs. The pharmacological effects of citalopram are almost 
exclusively ascribed to the S-enantiomer, and S-citalopram (escitalopram) was recently 
introduced as an antidepressant. The most common side effects of escitalopram include
nausea, vomiting, constipation, diarrhea, headache, sexual dysfunction, agitation, and
restlessness.  
Cases of hyperprolactinemia and galactorrhea induced by SSRIs including sertra-
line, fluoxetine, and fluvoxamine treatment were reported in some studies.
3-5 How-
ever, to the best of our knowledge there are no previous reports of galactorrhea accom-
panied by hyperprolactinemia in Korea. In this article, we present the case of a 36-year-
old woman who was treated with escitalopram for her major depressive disorder and 
developed galactorrhea with hyperprolactinemia that resolved upon discontinuation
of the drug. 
 
Case 
 
A 36-year-old woman with two children visited a psychiatric outpatient clinic on an
ambulatory basis. She had no history of endocrine or reproductive pathology or psychi-
atric problems. Although she had been receiving a conservative treatment for iron de-
ficiency anemia and transient hematuria, there was no specific hematologic and ne-
phrologic finding and she had not taken any dopamine antagonistic agents including 
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gastrointestinal motility drugs and antipsychotic agents 
except ferrous sulfate. Her son had been diagnosed with 
pervasive development disorder and mental retardation. 
She had suffered symptoms of depressed mood, nihilistic 
ideation, decreased volition, decreased psychomotor acti-
vity, loss of appetite, and sleep disturbance, which occurr-
ed after her son’s diagnosis 2 years ago. Diagnostic tests 
were performed to ascertain whether she had neurologic 
or any other systemic organic disease that could explain 
her symptoms. Following a detailed psychiatric examina-
tion with the Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I),
6 escitalopram 10 mg per day 
was prescribed to the patient with the diagnosis of major 
depressive disorder. She scored 26 on the Hamilton rating 
scale for depression (HRSD)
7,8 and 25 on the Beck depres-
sion inventory (BDI).
9,10 After 2 weeks of medication, her 
complaints declined, her HRSD score was 18 and her BDI 
score further decreased to 20. However, she developed gal-
actorrhea with breast pain (the nonpuerperal discharge of 
milk-containing fluid from the breast). She had no history 
of galactorrhea. She first noticed the discharge on treat-
ment day 14 and described it as white-creamy and from 
both nipples. She did not notice any bloody, greenish, or 
foul-smelling discharge nor report sexual dysfunction. She 
consulted her gynecologist, who recommended mammog-
raphy and breast ultrasonography. The results of these 
tests were normal. However, serum prolactin level on treat-
ment day 14 was 200 ng/mL (reference range: 1.2-24.2 
ng/mL). There were no abnormalities in blood chemistry, 
thyroid function tests, or electrocardiogram. She was re-
commended to undergo magnetic resonance imaging (M-
RI) of the hypothalamic/pituitary area to exclude mass 
lesions. However, she refused the test, which was not 
done. Because her galactorrhea developed after initiations 
of her medication with escitalopram, we stopped her medi-
cation. After cessation of the medication, the discharge 
abated and breast pain was relieved. Her serum prolactin 
level decreased to 2.38 ng/mL five days after discontinu-
ing escitalopram. 
 
Discussion 
 
As the use of SSRIs increases, clinicians can expect the 
appearance of uncommon side effects. For example, SSRIs 
can induce extrapyramidal symptoms, hyperprolactinemia, 
galactorrhea, and mammary hypertrophy, as well as gyn-
ecomastia. On the basis of several clinical reports and neu-
rophysiologic data about the inhibition of dopaminergic 
neurotransmission by SSRIs, one article
11 proposes to clas-
sify all of these SSRI-related side effects under the term 
dopamine-dependent side effects. 
This case demonstrates the development of hyperpro-
lactinemia, and subsequent galactorrhea while receiving 
escitalopram, which subsided shortly after the discontinua-
tion of the medication. In our approach to this patient, we 
sought to eliminate the most likely causes of galactorrhea. 
Hypothyroidism results in increased levels of thyrotropin-
releasing hormone, which increases prolactin secretion. 
Kidneys clear prolactin, and thus, kidney disease may 
cause secondary hyperprolactinemia. During pregnancy, 
and for up to 2 years after cessation of breast-feeding, gal-
actorrhea may be a normal finding. Because her measure-
ments of urea, creatinine, and thyroid-stimulating hormone 
were all normal, and a urine human chorionic gonadotro-
pin (HCG) test was negative, we were able to eliminate 
underlying kidney disease, hypothyroidism, or pregnancy 
as possible causes of galactorrhea. Although a transient 
surge (17.80±4.65 ng/mL) of prolactin following citalop-
ram administration was found in one human study,
12 a 
case with prolactin level (200 ng/mL) as extremely high 
as our report is very rare.   
Prolactin release has been studied extensively but is 
not yet completely understood. The factors involved in 
its control include dopamine, which is potent inhibitor of 
prolactin release, and thyrotropin releasing hormone and 
serotonin (5-HT), all of which promote prolactin release.   
It is not clear how serotonergic agents produce hyper-
prolactinemia. There is evidence that serotonin may sti-
mulate prolactin release directly via postsynaptic 5-HT 
receptors in the hypothalamus,
13 or indirectly via 5-HT 
mediated inhibition of tubuloinfundibular dopaminergic 
neurons.
14 Clearly, the interactions between the dopami-
nergic and serotonergic systems throughout the brain are 
complex. SSRIs can inhibit dopaminergic neurotransmis-
sion not only by their effects on dopamine secretion or 
recapture on dopaminergic receptors, but also indirectly 
through serotonergic mediation.
15 Complex changes of 
dopaminergic neurotransmission (mostly antidopaminergic 
effects) have been described with SSRIs.
16 However, there 
is little synaptic contact between serotonergic fibers and 
dopaminergic cells, indicating that if direct inhibition of 
dopamine cells occurs, it is through volume transmission 
of serotonin in the region.
17 There is more direct evidence 
for serotonergic stimulation of GABAergic neurons in the 
vicinity of tuberoinfundibular dopamine cells, based on 
the presence of 5-HT1A receptors on these cells.
18 Assum-
ing that these GABAergic cells are interneurons, their 5-
HT stimulation by SSRIs would result in inhibition of tu-
beroinfundibular dopamine cells, releasing the tonic inhi-
bition of proclactin. 
Gulsun et al.
19,20 have previously reported two cases 
with escitalopram-induced galactorrhea with and without 
prolactinemia. As far as we know this is the first report to 
show the case with escitalopram-induced galactorrhea and  
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hyperprolactinemia in Korea. While the galactorrhea some-
times seen after treatment with serotonergic medications 
appears to be a benign side effect, its occurrence offers 
new insights into the impact of serotonergic drugs on brain 
neurotransmitters and hormonal regulation. Clinicians 
should be aware of the possibility of galactorrhea in this 
context. Researchers should continue to explore the neuro-
hormonal effects of serotonergic medications to gain in-
sights into their effects. 
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